Shots:

• Genesis to receive an up front and is eligible to receive pre/ clinical and regulatory milestones along with royalties on sales of approved drugs emerges from the collaboration
• The collaboration leverages Genesis’ graph machine learning and drug discovery expertise to identify drug candidates for therapeutic targets across multiple disease areas
• Genesis has developed Dynamic PotentialNet and other neural network algorithms- examining drug-target complexes as flexible- spatial graphs- with the advantage of superior potency and selectivity prediction uniquely toward novel- previously undruggable targets and characterized therapeutic targets

 ­ Ref: BusinessWire | Image: Roche